Form 4: Tonix Pharmaceuticals Executive Granted Stock Options

Siobhan Fogarty, Chief Technology Officer of Tonix Pharmaceuticals, reports the acquisition of stock options.

Summary

• Siobhan Fogarty, the Chief Technology Officer of Tonix Pharmaceuticals Holding Corp., filed a Form 4 on February 27, 2025, reporting changes in beneficial ownership.
• The report details the grant of two stock option tranches on February 25, 2025.
• Each tranche consists of 13,500 options.
• The first tranche has an exercise price of $8.05, and the second has an exercise price of $10.0625.
• The options vest in installments starting February 25, 2026, and expire on February 25, 2035.
• Fogarty directly owns the reported securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting confidence in the company's future performance. The sentiment is neutral to positive.

Positives

• The grant of stock options to the CTO aligns her interests with those of the shareholders, incentivizing her to contribute to the company's success.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to reward long-term value creation.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the CTO to drive company growth and innovation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership team.

Key Dates